Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-12-12
2010-12-14
Marvich, Maria B (Department: 1633)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S325000, C435S366000, C536S023100, C536S023720
Reexamination Certificate
active
07851218
ABSTRACT:
The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus (“RCA”).
REFERENCES:
patent: 5837520 (1998-11-01), Shabram et al.
patent: 5891690 (1999-04-01), Massie
patent: 5932210 (1999-08-01), Gregory et al.
patent: 5994134 (1999-11-01), Giroux et al.
patent: 6146891 (2000-11-01), Condon et al.
patent: 6165779 (2000-12-01), Engler et al.
patent: 6210939 (2001-04-01), Gregory et al.
patent: 6248514 (2001-06-01), Hutchins et al.
patent: 6261823 (2001-07-01), Tang et al.
patent: 6312681 (2001-11-01), Engler et al.
patent: 6392069 (2002-05-01), Engler et al.
patent: 6395519 (2002-05-01), Fallaux et al.
patent: 6430595 (2002-08-01), Ferguson et al.
patent: 6544769 (2003-04-01), Frei et al.
patent: 6649158 (2003-11-01), LaFace
patent: 6783983 (2004-08-01), Condon et al.
patent: 6835557 (2004-12-01), Weissmann et al.
patent: 7001770 (2006-02-01), Atencio et al.
patent: 7074618 (2006-07-01), Li et al.
patent: 2002/0064860 (2002-05-01), Cannon-Carlson et al.
patent: 2002/0150557 (2002-10-01), Ramachandra et al.
patent: 2005/0074885 (2005-04-01), Vogels et al.
patent: 2006/0270041 (2006-11-01), Howe et al.
patent: WO 96/27677 (1996-09-01), None
patent: WO 1999/41416 (1999-08-01), None
patent: WO 2004/108088 (2004-12-01), None
patent: WO 2005/058368 (2005-06-01), None
patent: WO 2006/065827 (2006-06-01), None
patent: WO 2007/090392 (2007-06-01), None
Guo et al, Protein tolerance to random amino acid change, PNAS, 2004, vol. 101 (25), pp. 9205-9210.
Lesk et al, Prediction of Protein Function from Protein Sequence and Structure, p. 27 and 28, downloaded Sep. 16, 2007.
ATCC search results pp. 1-2, SL0003, downloaded Aug. 11, 2009.
ATCC search results pp. 1-2, SL0006, downloaded Aug. 11, 2009.
ATCC search results pp. 1-2, PTA-6231, downloaded Aug. 11, 2009.
ATCC search results pp. 1-2, PTA-6663, downloaded Aug. 11, 2009.
Babiss et al., “Adenovirus E1B Proteins Are Required for Accumulation of Late Viral mRNA and for Effects on Cellular mRNA Translation and Transport”,Molecular and Cellular Biology, 5(10):2552-2558 (Oct. 1985).
Bayley et al., “Adenovirus E1A proteins and transformation (Review)”,International Journal of Oncology, 5:425-444 (1994).
Branton et al., “Transformation By Human Adenoviruses”,Biochimca et Biophysica Acta, 780:67-94 (1985).
Condon et al., “Development of a Chinese Hamster Ovary Cell Line for Recombinant Adenovirus-Mediated Gene Expression”,Biotechnol. Prog., 19:137-143 (2003).
Demers et al., “Pharmacologic Indicators of Antitumor Efficacy for Oncolytic Virotherapy”,Cancer Research, 63:4003-4008 (Jul. 15, 2003).
Doronin et al., “Tumor-specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein”,J. Virol., 74(13):6147-6155 (Jul. 2000).
Fallaux et al., “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses”,Human Gene Therapy, 9:1909-1917 (Sep. 1, 1998).
Frisch et al., “Adenovirus-5 E1A: Paradox and Paradigm”,Nature Reviews Molecular Cell Biology, 3:441-452 (Jun. 2002).
Frisch, “Antioncogenic effect of adenovirus E1A in human tumor cells”,Proc. Natl. Acad. Sci. USA, 88:9077-9081 (Oct. 1991).
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”,J. Gen Virol., 36:59-74 (1977).
Harada et al., “p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication”,Journal of Virology, 73(7):5333-5344 (Jul. 1999).
Howe et al., “Retinoblastoma Growth Suppressor and a 300-kDa Protein Appear to Regulate Cellular DNA Synthesis”,Proc. Natl. Acad. Sci. USA, 87(15):5883-87 (Aug. 1990).
Howe et al., “Evaluation of E1-Mutant Adenoviruses as Conditionally Replicating Agents for Cancer Therapy”,Mol. Ther., 2(5):485-495 (Nov. 2000).
Howe et al., “Matching Complementing Functions of Transformed Cells with Stable Expression of Selected Viral Genes for Production of E1-Deleted Adenovirus Vectors”,Virology, 345(1):220-230 (2006).
Huyghe et al., “Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column Chromatography”,Human Gene Therapy, 6:1403-1416 (Nov. 1995).
Imler et al., “Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E-1 deleted adenovirus vectors”,Gene Therapy, 3:75-84 (1996).
Lochmuller et al., “Emergence of Early Region 1-Containing Replication-Competent Adenovirus in Stocks of Replication-Defective Adenovirus Recombinants (ΔE1+ΔE3) During Multiple Passages in 293 Cells”,Human Gene Therapy, 5:1485-1491 (Dec. 1994).
Louis et al., “Cloning and Sequencing of the Cellular—Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line”,Virology, 233:423-429 (1997).
Murakami et al., “A Single Short Stretch of Homology Between Adenoviral Vector and Packaging Cell Line Can Give Rise to Cytopathic Effect-Inducing, Helper-Dependent E1-Positive Particles”,Human Gene Therapy, 13:909-920. (May 20, 2002).
Mymryk et al., “Induction of apoptosis by adenovirus type 5 E1A in rat cells requires a proliferation block”,Oncogene, 9:1187-1193 (1994).
Querido et al., “Regulation of p53 Levels by the E1B 55-Kilodalton Protein and E4orf6 in Adenovirus-Infected Cells”,Journal of Virology, 71(5):3788-3798 (May 1997).
Rao et al., “The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins”,Proc. Natl. Acad. Sci. USA, 89:7742-7746 (Aug. 1992).
Shabram et al., “Analytical Anion-Exchange HPLC of Recombinant Type-5 Adenoviral Particles”,Human Gene Therapy, 8:453-465 (Mar. 1, 1997).
Shenk, “Adenoviridae: The Viruses and Their Replication”,Fields Virology, Third Edition, Chapter 67, 2:2111-2148 (1996).
White et al., “Adenovirus E1B 19-Kilodalton Protein Overcomes the Cytotoxicity of E1A Proteins”,Journal of Virology, 65(6): 2968-2978 (Jun. 1991).
Zhu et al., “Characterization of Replication-Competent Adenovirus Isolates from Large-Scale Production of a Recombinant Adenoviral Vector”,Human Gene Therapy, 10:113-121 (Jan. 1, 1999).
Amalfitano et al, “Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted”, Journal of Virology, vol. 72, No. 2, pp. 926-933 (1998).
Appleby et al, “A Novel Combination of Promoter and Enhancers Increases Transgene Expression in Vascular Smooth Muscle Cells In Vitro and Coronary Arteries In Vivo After Adenovirus-Mediated Gene Transfer”, Gene Therapy, vol. 10, pp. 1616-1622 (2003).
Aurisicchio et al, “Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis”, Journal of Virology, vol. 74, No. 10, pp. 4816-4823 (2000).
Bell et al, “The Protein CTCF Is Required for the Enhancer Blocking Activity of Vertebrate Insulators”, Cell, vol. 98, pp. 387-396 (1999).
Bell et al, “Insulators and Boundaries: Versatile Regulatory Elements in the Eukaryotic Genome”, Science, vol. 291, pp. 447-450 (2001).
Benedict et al, “Intravesical Ad-IFN-a Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nu
Howe John A.
Ralston, II Robert Orville
Sherrill Scott Joseph
Wills Ken N.
Marvich Maria B
Schering Corporation
LandOfFree
Cell lines for production of replication-defective adenovirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell lines for production of replication-defective adenovirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell lines for production of replication-defective adenovirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4184074